# Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.

> **NCT00258765** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Zoledronic Acid
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00258765
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2006-11
- **Final completion:** —
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Poor recruitment \& not feasible to continue
- **Last updated:** 2010-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258765, "Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00258765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*